Quadrant Private Wealth Management, LLC Lineage Cell Therapeutics, Inc. Transaction History
Quadrant Private Wealth Management, LLC
- $391 Million
- Q1 2025
A detailed history of Quadrant Private Wealth Management, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Quadrant Private Wealth Management, LLC holds 10,000 shares of LCTX stock, worth $6,899. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$6,899
Previous $5,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding LCTX
# of Institutions
138Shares Held
108MCall Options Held
8KPut Options Held
3K-
Broadwood Capital Inc New York, NY49.6MShares$34.2 Million1.86% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$6.15 Million0.0% of portfolio
-
Defender Capital, Llc.6.31MShares$4.35 Million1.19% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$3.89 Million3.45% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $117M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...